Immunotherapeutic approaches aim to tip this balance in favour of anti-tumour immunity by targeting Treg activation or inhibitory pathways such as the programmed cell death protein 1 (PD-1), its ligands (PD-L1 and PD-L2) [16,17,18] or CTLA-4. This evidence concerns the gene PDCD1 and neoplasm.